The effects of probiotics on barrier function and mucosal pouch microbiota during maintenance treatment for severe pouchitis in patients with ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 7, 2013, Pages 772-783

  Persborn, M ^a,b,c   Gerritsen, J ^d,e   Wallon, C ^a,b   Carlsson, A ^a   Akkermans, L M A ^f   Soderholm J D ^a,b  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b Centre of Surgery and Oncology   (Sweden)

^c Region Jönköping County   (Sweden)

^d WAGENINGEN UNIVERSITY   (Netherlands)

^e WINCLOVE PROBIOTICS   (Netherlands)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; ECOLOGIC; METRONIDAZOLE; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTEROIDETES; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM BIFIDUM; CLINICAL ARTICLE; CLOSTRIDIUM; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; ILEITIS; ILEUM MUCOSA; INTESTINE BIOPSY; INTESTINE FLORA; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS PARACASEI; LACTOBACILLUS PLANTARUM; LACTOBACILLUS SALIVARIUS; LACTOCOCCUS LACTIS; MAINTENANCE THERAPY; MALE; MICROBIAL DIVERSITY; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; REMISSION; SINGLE DRUG DOSE; SPECIES COMPOSITION; ULCERATIVE COLITIS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BIOPSY; COLITIS, ULCERATIVE; COLONIC POUCHES; ESCHERICHIA COLI; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; MICROBIOTA; MIDDLE AGED; PERMEABILITY; POUCHITIS; PROBIOTICS; RECURRENCE;

EID: 84883486415     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12451     Document Type: Article

References (56)

1. McLaughlin SD, Clark SK, Tekkis PP, Ciclitira PJ, Nicholls RJ,. Review article: restorative proctocolectomy, indications, management of complications and follow-up-a guide for gastroenterologists. Aliment Pharmacol Ther 2008; 27: 895-909.
2. Schouten WR,. Pouchitis. Mediators Inflamm 1998; 7: 175-81.
3. Turroni S, Vitali B, Candela M, et al,. Antibiotics and probiotics in chronic pouchitis: a comparative proteomic approach. World J Gastroenterol 2010; 16: 30-41.
4. Sagar PM, Taylor BA, Godwin P, et al,. Acute pouchitis and deficiencies of fuel. Dis Colon Rectum 1995; 38: 488-93.
5. Levin KE, Pemberton JH, Phillips SF, Zinsmeister AR, Pezim ME,. Role of oxygen free radicals in the etiology of pouchitis. Dis Colon Rectum 1992; 35: 452-6.
6. Kuisma J, Jarvinen H, Kahri A, Farkkila M,. Factors associated with disease activity of pouchitis after surgery for ulcerative colitis. Scand J Gastroenterol 2004; 39: 544-8.
7. Sandborn WJ, Tremaine WJ, Batts KP, et al,. Fecal bile acids, short-chain fatty acids, and bacteria after ileal pouch-anal anastomosis do not differ in patients with pouchitis. Dig Dis Sci 1995; 40: 1474-83.
8. Coffey JC, Rowan F, Burke J, Dochery NG, Kirwan WO, O'Connell PR,. Pathogenesis of and unifying hypothesis for idiopathic pouchitis. Am J Gastroenterol 2009; 104: 1013-23.
9. Brett PM, Yasuda N, Yiannakou JY, et al,. Genetic and immunological markers in pouchitis. Eur J Gastroenterol Hepatol 1996; 8: 951-5.
10. Carter MJ, Di Giovine FS, Cox A, et al,. The interleukin 1 receptor antagonist gene allele 2 as a predictor of pouchitis following colectomy and IPAA in ulcerative colitis. Gastroenterology 2001; 121: 805-11.
11. Facklis K, Plevy SE, Vasiliauskas EA, et al,. Crohn's disease-associated genetic marker is seen in medically unresponsive ulcerative colitis patients and may be associated with pouch-specific complications. Dis Colon Rectum 1999; 42: 601-5.
12. Madden MV, McIntyre AS, Nicholls RJ,. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci 1994; 39: 1193-6.
13. Shen B, Achkar JP, Lashner BA, et al,. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001; 7: 301-5.
14. Gerritsen J, Smidt H, Rijkers GT, de Vos WM,. Intestinal microbiota in human health and disease: the impact of probiotics. Genes Nutr 2011; 6: 209-40.
15. Onderdonk AB, Dvorak AM, Cisneros RL, et al,. Microbiologic assessment of tissue biopsy samples from ileal pouch patients. J Clin Microbiol 1992; 30: 312-7.
16. Ruseler-van Embden JG, Schouten WR, van Lieshout LM,. Pouchitis: result of microbial imbalance? Gut 1994; 35: 658-64.
17. Ohge H, Furne JK, Springfield J, Rothenberger DA, Madoff RD, Levitt MD,. Association between fecal hydrogen sulfide production and pouchitis. Dis Colon Rectum 2005; 48: 469-75.
18. Iwaya A, Iiai T, Okamoto H, et al,. Change in the bacterial flora of pouchitis. Hepatogastroenterology 2006; 53: 55-9.
19. Komanduri S, Gillevet PM, Sikaroodi M, Mutlu E, Keshavarzian A,. Dysbiosis in pouchitis: evidence of unique microfloral patterns in pouch inflammation. Clin Gastroenterol Hepatol 2007; 5: 352-60.
20. Lim M, Adams JD, Wilcox M, Finan P, Sagar P, Burke D,. An assessment of bacterial dysbiosis in pouchitis using terminal restriction fragment length polymorphisms of 16S ribosomal DNA from pouch effluent microbiota. Dis Colon Rectum 2009; 52: 1492-500.
21. McLaughlin SD, Walker AW, Churcher C, et al,. The bacteriology of pouchitis: a molecular phylogenetic analysis using 16S rRNA gene cloning and sequencing. Ann Surg 2010; 252: 90-8.
22. Zella GC, Hait EJ, Glavan T, et al,. Distinct microbiome in pouchitis compared to healthy pouches in ulcerative colitis and familial adenomatous polyposis. Inflamm Bowel Dis 2011; 17: 1092-100.
23. Tannock GW, Lawley B, Munro K, et al,. Comprehensive analysis of the bacterial content of stool from patients with chronic pouchitis, normal pouches, or familial adenomatous polyposis pouches. Inflamm Bowel Dis 2012; 18: 925-34.
24. Hinata M, Kohyama A, Ogawa H, et al,. A shift from colon- to ileum-predominant bacteria in ileal-pouch feces following total proctocolectomy. Dig Dis Sci 2012; 57: 2965-74.
25. Bibiloni R, Fedorak RN, Tannock GW, et al,. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005; 100: 1539-46.
26. Kruis W, Fric P, Pokrotnieks J, et al,. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53: 1617-23.
27. Gionchetti P, Rizzello F, Helwig U, et al,. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003; 124: 1202-9.
28. Gosselink MP, Schouten WR, van Lieshout LM, Hop WC, Laman JD, Ruseler-van Embden JG,. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum 2004; 47: 876-84.
29. Shen B, Brzezinski A, Fazio VW, et al,. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther 2005; 22: 721-8.
30. Mimura T, Rizzello F, Helwig U, et al,. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53: 108-14.
31. Gionchetti P, Rizzello F, Venturi A, et al,. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 305-9.
32. Laake KO, Line PD, Grzyb K, et al,. Assessment of mucosal inflammation and blood flow in response to four weeks' intervention with probiotics in patients operated with a J-configurated ileal-pouch-anal-anastomosis (IPAA). Scand J Gastroenterol 2004; 39: 1228-35.
33. Kuisma J, Mentula S, Jarvinen H, Kahri A, Saxelin M, Farkkila M,. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 2003; 17: 509-15.
34. Lutgendorff F, Akkermans LM, Soderholm JD,. The role of microbiota and probiotics in stress-induced gastro-intestinal damage. Curr Mol Med 2008; 8: 282-98.
35. Wallon C, Persborn M, Jonsson M, et al,. Eosinophils express muscarinic receptors and corticotropin-releasing factor to disrupt the mucosal barrier in ulcerative colitis. Gastroenterology 2011; 140: 1597-607.
36. Madsen K, Cornish A, Soper P, et al,. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001; 121: 580-91.
37. van Minnen LP, Timmerman HM, Lutgendorff F, et al,. Modification of intestinal flora with multispecies probiotics reduces bacterial translocation and improves clinical course in a rat model of acute pancreatitis. Surgery 2007; 141: 470-80.
38. Lamprecht M, Bogner S, Schippinger G, et al,. Probiotic supplementation affects markers of intestinal barrier, oxidation, and inflammation in trained men; a randomized, double-blinded, placebo-controlled trial. J Int Soc Sports Nutr 2012; 9: 45.
39. Sandborn WJ, Tremaine WJ, Batts KP, Pemberton JH, Phillips SF,. Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin Proc 1994; 69: 409-15.
40. Wallon C, Braaf Y, Wolving M, Olaison G, Soderholm JD,. Endoscopic biopsies in Ussing chambers evaluated for studies of macromolecular permeability in the human colon. Scand J Gastroenterol 2005; 40: 586-95.
41. Wallon C, Yang PC, Keita AV, et al,. Corticotropin-releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro. Gut 2008; 57: 50-8.
42. Soderholm JD, Hedman L, Artursson P, et al,. Integrity and metabolism of human ileal mucosa in vitro in the Ussing chamber. Acta Physiol Scand 1998; 162: 47-56.
43. Velin AK, Ericson AC, Braaf Y, Wallon C, Soderholm JD,. Increased antigen and bacterial uptake in follicle associated epithelium induced by chronic psychological stress in rats. Gut 2004; 53: 494-500.
44. Rajilic-Stojanovic M, Heilig HG, Molenaar D, et al,. Development and application of the human intestinal tract chip, a phylogenetic microarray: analysis of universally conserved phylotypes in the abundant microbiota of young and elderly adults. Environ Microbiol 2009; 11: 1736-51.
45. Salonen A, Nikkila J, Jalanka-Tuovinen J, et al,. Comparative analysis of fecal DNA extraction methods with phylogenetic microarray: effective recovery of bacterial and archaeal DNA using mechanical cell lysis. J Microbiol Methods 2010; 81: 127-34.
46. Leps J, Smilauer P,. Multivariate Analysis of Ecological Data Using CANOCO. 1st ed. Cambridge: Cambridge University Press, 2003.
47. Kroesen AJ, Leistenschneider P, Lehmann K, et al,. Increased bacterial permeation in long-lasting ileoanal pouches. Inflamm Bowel Dis 2006; 12: 736-44.
48. Kroesen AJ, Dullat S, Schulzke JD, Fromm M, Buhr HJ,. Permanently increased mucosal permeability in patients with backwash ileitis after ileoanal pouch for ulcerative colitis. Scand J Gastroenterol 2008; 43: 704-11.
49. Keita AV, Salim SY, Jiang T, et al,. Increased uptake of non-pathogenic E. coli via the follicle-associated epithelium in longstanding ileal Crohn's disease. J Pathol 2008; 215: 135-44.
50. Duffy M, O'Mahony L, Coffey JC, et al,. Sulfate-reducing bacteria colonize pouches formed for ulcerative colitis but not for familial adenomatous polyposis. Dis Colon Rectum 2002; 45: 384-8.
51. Ohland CL, Macnaughton WK,. Probiotic bacteria and intestinal epithelial barrier function. Am J Physiol Gastrointest Liver Physiol 2010; 298: G807-19.
52. Shibolet O, Karmeli F, Eliakim R, et al,. Variable response to probiotics in two models of experimental colitis in rats. Inflamm Bowel Dis 2002; 8: 399-406.
53. Ulisse S, Gionchetti P, D'Alo S, et al,. Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am J Gastroenterol 2001; 96: 2691-9.
54. Gionchetti P, Amadini C, Rizzello F, Venturi A, Campieri M,. Review article: treatment of mild to moderate ulcerative colitis and pouchitis. Aliment Pharmacol Ther 2002; 16 (Suppl. 4): 13-9.
55. Rayes N, Seehofer D, Theruvath T, et al,. Effect of enteral nutrition and synbiotics on bacterial infection rates after pylorus-preserving pancreatoduodenectomy: a randomized, double-blind trial. Ann Surg 2007; 246: 36-41.
56. Rayes N, Seehofer D, Theruvath T, et al,. Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation-a randomized, double-blind trial. Am J Transplant 2005; 5: 125-30.